Progress and Promise in the Treatment of Indolent Lymphomas

Progress and Promise in the Treatment of Indolent Lymphomas Peter McLaughlin Oncologist 2002; 7: 217-225. Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine regarding lymphomas and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe subsets of patients with indolent lymphoma for whom cure may be a realistic goal. Describe the ways by which the polymerase chain reaction for bcl-2 can be utilized to monitor patients with follicular lymphoma. Identify immunotherapy approaches that have shown promising results for patients with indolent lymphoma. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jun. 13, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Jan. 8, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.